Company Overview: Check-Cap

About the Company

Check-Cap
Tweeter Linkedin

Check-Cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.

The Check-Cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. Check-Cap’s advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures.

Founded in early 2005, Check-Cap recruited a team of world-class experts in physics, software engineering, electronics, mechanics and physiology, who have been developing a multi-disciplinary imaging solution for imaging and screening of the colon. The system includes a capsule, a receiver, proprietary imaging software and an associated database for web based access and analysis.

Check-Cap’s advanced technology has been proven in animals and promises to offer several significant advantages compared to other colonic screening procedures.

Colorectal cancer is the Western world’s second largest cancer killer, despite being largely preventable and/or treatable with early screening. Check-Cap’s technology is designed to be the first to offer CRC screening through a structural exam without the pain, discomfort and embarrassment experienced during currently available screening methods, and thus is uniquely positioned to increase screening compliance without compromising accuracy. We intend to develop our technology into the next breakthrough, gold standard in colon cancer screening to address the need of an estimated 35 million patients annually in a fast-growing $25B market.


Investor Toolkit

Company News

  • Check-Cap Ltd. Announces Closing of $2.69 Million Financing

    ISFIYA, Israel and BOSTON, June 2, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced...

  • Check-Cap Ltd. Announces $2.69 Million Financing

    ISFIYA, Israel and BOSTON, May 30, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that...

  • Check-Cap and GE Healthcare Achieve Development Milestone in High-volume X-Ray Capsule Manufacturing Collaboration

    ISFIYA, Israel and CHALFONT ST. GILES, England, May 9, 2017 /PRNewswire/ — Check-Cap Ltd. (NASDAQ: CHEK, CHEKW), a clinical-stage company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening and GE Healthcare (GE) today announced...

  • Check-Cap Reports First Quarter 2017 Financial Results

    ISFIYA, Israel, May 9, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK; NASDAQ: CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today provided a...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address